A comprehensive dosimetric comparison between 131Cs and 125I brachytherapy sources for COMS eye plaque implant

Brachytherapy

Volumn 9, Issue 4, 2010, Pages 362-372

  Zhang, Hualin ^a   Martin, Douglas ^a   Chiu Tsao, Sou Tung ^b   Meigooni, Ali ^c   Thomadsen, Bruce R ^d,e  

^a OHIO STATE UNIVERSITY   (United States)

^b Quality MediPhys LLC   (United States)

^c NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

125I; 131Cs; Brachytherapy; COMS eye plaque; MCNPX

Indexed keywords

CESIUM 131; GOLD ALLOY; IODINE 125; SILASTIC; WATER;

ACCURACY; ARTICLE; BRACHYTHERAPY; DOSE CALCULATION; DOSIMETRY; EYE PLAQUE BRACHYTHERAPY; EYE TUMOR; EYEBALL; IMPLANT; PRESCRIPTION; PRIORITY JOURNAL; SCLERA; SIMULATION; TREATMENT PLANNING; TUMOR VOLUME;

BRACHYTHERAPY; CESIUM RADIOISOTOPES; EYE NEOPLASMS; FEMALE; GOLD; HUMANS; IODINE RADIOISOTOPES; MALE; MELANOMA; MONTE CARLO METHOD; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 77957331897     PISSN: 15384721     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brachy.2009.07.007     Document Type: Article

References (32)

1. Finger P.T. ″ Radiation therapy for choroidal melanoma.″ Survey Ophthalmol 1997, 42:215-232.
2. Diener-West M., Earle J.D., Fine S.L., et al. Collaborative Ocular Melanoma Study Group. "The COMS randomized trial of Iodine 125 brachytherapy for choroidal melanoma III: Initial mortality findings. COMS report No.18." Arch Ophthalmol 2001, 119:969-982.
3. Jampol L.M., Moy C.S., Murray T.G., et al. The COMS randomized trial of iodine-125 brachytherapy for choroidal melanoma: IV, Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002, 109:2197-2206. For the COMS Follow Up of Plaqued Eyes Working Group.
4. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma V. Twelve-year mortality rates and prognostic factors: COMS Report No. 28. Arch Ophthalmol 2006, 124:1684-1693. Collaborative Ocular Melanoma Study (COMS) Group.
5. Nag S., Quivey J.M., Earle J.D., et al. The American Brachytherapy Society recommendations for brachytherapy of uveal melanoma. Int J Radiat Oncol Biol Phys 2003, 56:544-555.
6. Nag S., Wang D., Wu H., et al. Custom-made "Nag" eye plaques for 125I brachytherapy. Int J Radiat Oncol Biol Phys 2003, 56:1373-1380.
7. Granero D., Perez-Calatayud J., Ballester F., et al. Dosimetrc study of the 15 mm ROPES eye plaque. Med Phys 2004, 31:3330-3336.
8. Chiu-Tsao S. Episcleral eye plaques for treatment of intra-ocular malignancies and benign diseases. Brachytherapy physics 2005, 673-705. Medical Physics Publishing Company, Madison, WI. 2nd ed. B. Thomadsen, M.J. Rivard, W. Butler (Eds.).
9. Astrahan M. Improved treatment planning for COMS eye plaques. Int J Radiat Oncol Biol Phys 2005, 61:1227-1242.
10. Chiu-Tsao S., Anderson L.L., O'brien K., et al. Dosimetry for 125I seed (model 6711) in eye plaques. Med Phys 1993, 20:383-389.
11. de la Zerda A., Chiu-Tsao S., Lin J., et al. 125I seed eye plaque dose distribution including penumbra characteristics. Med Phys 1986, 23:407-418.
12. Wu A., Krasin F. Film dosimetry analyses on the effect of gold shielding for iodine-125 eye plaque therapy for choroidal melanoma. Med Phys 1990, 17:843-846.
13. Astrahan M.A., Szechter A., Finger P.T. Design and dosimetric considerations of a modified COMS plaque: the reusable "seed-guide" insert. Med Phys 2005, 32:2706-2716.
14. Finger P.T., Berson A., Ng T., et al. Palladium-103 plaque radiotherapy for choroidal melanoma: an 11-year study. Int J Radiat Oncol Biol Phys 2002, 54:1438-1445.
15. Damato B., Patel I., Campbell I.R., et al. Local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 2005, 63:385-391.
16. Murphy M.K., Piper R.K., Greenwood L.R., et al. Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy. Med Phys 2004, 31:1529-1538.
17. Melhus C.S., Rivard M. COMS eye plaque brachytherapy dosimetry simulations for 103Pd, 125I and 131Cs. Med Phys 2008, 35:3364-3371.
18. Rivard M.J., Melhus C.S., Sioshansi S., et al. The impact of prescription depth, dose rate, plaque size, and source loading on the central axis using 103Pd, 125I, and 131Cs. Brachytherapy 2008, 7:327-335.
19. Chen Z., Bongiorni P., Nath R. Dose rate constant of a cesium-131 interstitial brachytherapy seed measured by thermoluminescent dosimetry and gamma-ray spectrometry. Med Phys 2005, 32:3279-3285.
20. Wittman R.S., Fisher D.R. Multiple-estimate Monte Carlo calculation of the dose rate constant for a cesium-131 interstitial brachytherapy seed. Med Phys 2007, 34:49-54.
21. Rivard M.J. Brachytherapy dosimetry parameters calculated for a 131Cs source. Med Phys 2007, 34:754-762.
22. Wang J., Zhang H. Dosimetric characterization of model CS-1 cesium-131 brachytherapy source in water phantoms and human tissues with MCNP5 Monte Carlo simulation. Med Phys 2008, 35:1571-1579.
23. Meigooni A.S., Hayes J., Zhang H., et al. Experimental determination of dosimetric characteristics of IsoAid advantage 125I brachytherapy source. Med Phys 2002, 29:2152-2158.
24. Solberg T.D., Demarco J.J., Luxton G., et al. Dosimetric parameters of three new solid core I-125 brachytherapy sources. J Appl Clin Med Phys 2002, 3:119-134.
25. Taylor R.E.P., Rogers D.W.O. An EGSnrc Monte Carlo calculated data-base of TG43 parameters. Med Phys 2008, 35:4228-4241.
26. Hendricks JS, Mckinney GW, Waters LS, et al. "MCNPX user's manual, version 2.5e." LA-UR-04-0569. Report of Los Alamos National Laboratory, 2004.
27. Hubble J.H., Seltzer S.M. Tables of of X-Ray mass attenuation coefficients and mass energy-absorption coefficients from 1 keV to 20 MeV for elements Z=1 to 92 and 48 additional substances of dosimetric interest. NIST IR 1996, 5632.
28. RSICC computer code collection "Monte Carlo N-particle Transport Code System" 2000, Los Alamos National Laboratory, Los Alamos, New Mexico.
29. Zhang H., Baker C., Mckinsey R., et al. Dose verification with Monte Carlo technique for prostate brachytherapy implant with 125I sources. Med Dosim 2005, 30:85-91.
30. NUDAT 2.0 National nuclear data center, Brookhavern national laboratory Accessed August 18, 2008. http://www.nndc.bnl.gov/nudat2/indexjsp.
31. Rivard M.J., Coursey B.M., DeWerd L.A., et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004, 31:633-674.
32. Williamson J.F., Rivard M.J. Chapter 15: "Quantitative dosimetry methods for brachytherapy" Brachytherapy physics 2005, Medical Physics Publishing, Madison, WI. 2nd ed. B. Thomadsen, M. Rivard, W. Butler (Eds.).